The CRyPTIC Consortium measured the antibiotic susceptibility of its 10,000th sample sometime around the end of 2018.

Each sample is incubated on a dry 96-well microdilution plate that is manufactured by Thermo Fisher. CRyPTIC has recently updated the design of its microtitre plate to remove one drug that was found not to be reproducible (para-aminosalicylic acid). This freed up some wells that were used to extend the concentration ranges of a few of the remaining 13 antituberculars on the plate.